Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-02-27
2007-02-27
O'Hara, Eileen B. (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S184100, C424S198100, C530S350000
Reexamination Certificate
active
10623189
ABSTRACT:
Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.
REFERENCES:
patent: 5521283 (1996-05-01), DiMarchi et al.
patent: 5525705 (1996-06-01), DiMarchi et al.
patent: 5532336 (1996-07-01), DiMarchi et al.
patent: 5552522 (1996-09-01), DiMarchi et al.
patent: 5552523 (1996-09-01), Basinski et al.
patent: 5552524 (1996-09-01), Basinski et al.
patent: 5554727 (1996-09-01), Basinski et al.
patent: 5559208 (1996-09-01), Basinski et al.
patent: 5563243 (1996-10-01), DiMarchi et al.
patent: 5563244 (1996-10-01), DiMarchi et al.
patent: 5563245 (1996-10-01), DiMarchi et al.
patent: 5567678 (1996-10-01), DiMarchi et al.
patent: 5567803 (1996-10-01), Basinski et al.
patent: 5569743 (1996-10-01), DiMarchi et al.
patent: 5569744 (1996-10-01), Basinski et al.
patent: 5574133 (1996-11-01), DiMarchi et al.
patent: 5580954 (1996-12-01), DiMarchi et al.
patent: 5594101 (1997-01-01), Becker et al.
patent: 5594104 (1997-01-01), Basinski et al.
patent: 5605886 (1997-02-01), Basinski et al.
patent: 5614379 (1997-03-01), MacKellar
patent: 5691309 (1997-11-01), Basinski et al.
patent: 5719266 (1998-02-01), DiMarchi et al.
patent: 5756461 (1998-05-01), Stephens
patent: 5922678 (1999-07-01), Stephens
patent: 6258932 (2001-07-01), Vahlne
patent: 6899892 (2005-05-01), Gallaher et al.
patent: 725078 (1996-01-01), None
patent: 725079 (1996-01-01), None
patent: 741187 (1996-04-01), None
patent: 745610 (1996-04-01), None
patent: 736599 (1996-05-01), None
patent: 744408 (1996-05-01), None
patent: 835879 (1997-10-01), None
patent: WO 96/05309 (1996-02-01), None
patent: WO 96/22308 (1996-07-01), None
patent: WO 96/27385 (1996-07-01), None
patent: WO 96/23513 (1996-08-01), None
patent: WO 96/23514 (1996-08-01), None
patent: WO 96/23515 (1996-08-01), None
patent: WO 96/23516 (1996-08-01), None
patent: WO 96/23517 (1996-08-01), None
patent: WO 96/23518 (1996-08-01), None
patent: WO 96/23519 (1996-08-01), None
patent: WO 96/31526 (1996-10-01), None
patent: WO 96/34111 (1996-11-01), None
patent: WO 96/34885 (1996-11-01), None
patent: WO 96/35787 (1996-11-01), None
patent: WO 96/37517 (1996-11-01), None
patent: WO 96/40912 (1996-12-01), None
patent: WO 97/00886 (1997-01-01), None
patent: WO 97/06816 (1997-02-01), None
patent: WO 97/16550 (1997-05-01), None
patent: WO 97/18833 (1997-05-01), None
patent: WO 97/20933 (1997-06-01), None
patent: WO 97/38014 (1997-10-01), None
patent: WO 97/46585 (1997-12-01), None
patent: WO 98/08512 (1998-03-01), None
patent: WO 00/20872 (1998-05-01), None
patent: WO 98/28427 (1998-07-01), None
Gavrilova et al., Leptin and diabetes in lipoatrophic mice, NATURE, Vo. 403, Feb. 24, 2000, pp. 850-851.
Chen et al., Disappearance of body fat in normal rats induced by adenovirus-mediated leptin gene therapy, PNAS, Vo. 93, pp. 14795-14999, Dec. 1996.
Reitman et al., A-ZIP/F1 mice lacking white fat: a model for understanding lipoatrophic diabetes, International Journal of Obesity and Related Metabolic Disorders: Journal of the International Association for the Study of Obesity, Nov. 2000, vol. 24, Suppl 4, pp. S11-4.
Cao, H., et al., “Nuclear Lamin A/C R482q Mutation in Canadian Kindreds With Dunnigan-Type Familial Partial Lipodystrophy,”Hum Mol Genent. 2000; 0:109-12.
Cosidine, R.V., et al., “Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans,”N Engl J Med. 1996; 334:292-5.
Ebihara, K., et al., “Transgenic Overexpression of Leptin Rescues Insulin Resistance and Diabetes in A Mouse Model of Lipoatrophic Diabetes,”Diabetes2001; 50:1440-8.
Farooqi, I.S., et al., “Effects of Recombinant Leptin Therapy in A Child With Congenital Leptin Deficiency,”N Engl J Med. 1999; 341:879-84.
Feskanich, D., et al., “Reproductability and Validity of Food Intake Measurements From A Semiquantitative Food Frequency Questionnaire,”J Am Diet Assoc. 1993; 93:790-6.
Fruebis, J., et al., “Proteolytic Cleavage Product of 30-Kda Adipocyte Complement-Related Protein Increases Fatty Acid Oxidation in Muscle and Causes Weight Loss in Mice,”Proc Nat1 Acad Sci U S A2001; 98:2005-L0.
Garg, A., et al., “Adipose Tissue Distribution Pattern in Patients With Familiar Partial Lipodystrophy (Dunnigan Variety),”J Clin Endocrinal Metab1999; 84:170-4.
Garg, A., et al., “Peculiar Distribution of Adipose Tissue in Patients With Congenital Generalized Lipodystrophy,”J Clin Endocrinol Metab. 1992; 75:358-61.
Garg, A., et al., “Lipodystrophies,”Am J Med. 2000; 108:143-52.
Gavrilova, O., et al., “Surgical Implantation of Adipose Tissue Reverses Diabetes in Lipoatrophic Mice,”J Clin Invest2000; 105: 271-8.
Gotto, A.M., Jr., “Triglyceride As a Risk Factor For Coronary Artery Disease,”Am J Cariol1998; 82: 22Q25Q.
Halaas, J.L., et al., “Weight-Reducing Effects of the Plasma Protein Encoded By the Obese Gene,”Science1995; 269:543-6.
Harrison, L.C., et al., “Correlation Between Insulin Receptor Binding in Isolated Fat Cells and Insulin Sensitivity in Obese Human Subjects,”J Clin Invest1976; 58:1435-41.
Heymsfield, S.B., et al., “Recombinant Leptin For Weight Loss in Obese and Lean Adults: A Randomized, Contolled, Dose-Escalation Trial [See Comments],”Jama1999; 282:1568-75.
“Intensive Blood-Glucose Control With Sulphonylureas Or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 33),”UK Prospective Diabetes Study(UKPDS)Group, Lancet 1998; 352:837-53.
Kreisberg, R.A., “Diabetic Dyslipidemia,” Am J Cardiol 1998; 82:67U-73U.
Lambrinoudaki, I., et al., “Body Composition Assessment By Dual-Energy X-Ray Absorptionmetry: Comparison of Prone and Supine Measurements,”Metabolism1998; 47:1379-82.
Lawrence, R.D., “Lipodystrophy and Hepatomegaly With Diabetes, Lipaemia, and Other Metabolic Disturbances: A Case Throwing New Light On the Action of Insulin,”Lancet1946; 1:724-731 and 773-775.
Luyckx, F.H., et al., “Non-Alcoholic Steatohepatitis: Association With Obesity and Insulin Resistance, and Influence of Weight Loss,”Diabetes Metab2000; 26:98-106.
Magre, J., et al., “Identification of the Gene Altered in Berardinelli-Seip Congenital Lipodystrophy On Chromosome 1lq13,”Nat Genet2001; 28:365-70.
Manton, N.D., et al., “Non-Alcoholic Steatohepatitis in Children and Adolescents,”Med J Aust2000; 173:476-9.
Mantzoros, C.S., et al., “Editorial: Leptin As A Therapeutic As a Therapeutic Agent-Trials and Tribulations,”J Clin Endocrinal Metab2000; 85:4000-2.
Moitra, J., et al., “Life Without White Fat: A Transgenic Mouse,”Genes Dev1998; 12: 3168-81.
Montague, C.T., et al., “Congenital Leptin Deficiency Is Associated With Severe Early Onset Obesity in Humans,”Nature1997; 387:903-8.
Pelleymountier, M.A., et al., “Effects of the Obese Gene Product On Body Weight Regulation in ob/ob Mice,”Science1995; 269:540-3.
Peters, A.L., et al., “The New Diagnostic Criteria For Diabetes: The Impact on Management of Diabetes and Macrovascular Risk Factors,”Am J Med1998; 105:15s-19s.
Reitman, M.L., et al., “Lipoatrophy Revisited,”Trends Endoctrinol Metab. 2000; 11:410-6.
Shimomura, I., et al., “Decreased IRS-2 and Increased SREBP-1c Lead To Mixed Resistance and Sensitivity in Livers of Lipodystrophic and ob/obMice,”Mol Cel2000; 6:77-86.
Shimomura, I., et al., “Insulin Resistance and Diabetes Mellitus in Transgenic Mice Expressing Nuclear SREBP
DePaoli Alexander M.
Garg Abhimanyu
Oral Elif A.
Taylor Simeon I.
Amgen Inc.
Amylin Pharmaceuticals, Inc.
O'Hara Eileen B.
LandOfFree
Use of leptin for treating human lipoatrophy and method of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of leptin for treating human lipoatrophy and method of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of leptin for treating human lipoatrophy and method of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3835632